Clinical trial · Interventional
PRecision Oncology Evidence Development in Cancer Treatment - Liquid
PRecision Oncology Evidence Development in Cancer Treatment - Liquid AKA the Real World Clinical Utility of ctDNA Analysis for Decision Making and Access to Precision Therapy for Advanced Cancer Patients in BC: The RAPTor Sub-study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The current standard of care for molecular characterization of tumors is tissue based next generation sequencing (NGS) panel. Liquid biopsies (ie blood) are of increasing interest and have been implemented as a diagnostic tool in some countries. This study compares tissue based and liquid based testing to evaluate the detection rate and cost consequence of using this new tool in BC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FoundationOne liquid CDx | Diagnostic Test | — | UNRESOLVED |
| Quality of life questionnaires | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Simultaneous - FoundationOne liquid CDx
- description
- Patients undergoing FoundationOne liquid CDx while tissued-based NGS panel is in progress or reported within 4 weeks of enrollment
- interventionNames
- Diagnostic Test: FoundationOne liquid CDx
- Behavioral: Quality of life questionnaires
- type
- EXPERIMENTAL
- label
- Simultaneous - no additional testing
- description
- Patients undergoing no additional testing while tissue-based NGS panel is in progress or reported within 4 weeks of enrolment
- interventionNames
- Behavioral: Quality of life questionnaires
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 * Patients with metastatic malignancy * Patients undergoing tissue based molecular characterization by tissue based NGS panel Part A - Simultaneous * Tissue based NGS panel requested or reported within 4 weeks of enrolment * Patients receiving treatment at BC Cancer Part B - Sequential * Tissue based NGS oncopanel does NOT identify a somatic tier 1 variant of strong clinical significance OR fails/not feasible due to insufficient tissue * BC Cancer - Provincial (not including Vancouver Centre) Exclusion Criteria: * Patients not available for follow up * Patients who are not willing to consider systemic treatment options
References
Publications (0)
Data not yet available